Drug Target Review2025-09-02T09:00:00
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-31T06:00:00Z
Contributor Dr Davinder Ramsingh, Drug Target Review
2023-07-11T16:13:06
Sponsored by Agilent
2023-05-10T11:18:16
Sponsored by Revvity
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
2023-06-20T12:34:32
Sponsored by NanoTemper Technologies
2023-03-28T11:38:32
Sponsored by Bio-Techne
2023-11-20T13:43:43
Sponsored by Merck
Site powered by Webvision Cloud